What is HC Wainwright’s Forecast for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a report released on Wednesday, March 25th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings per share of ($1.28) for the year, up from their previous forecast of ($1.35). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($1.24) EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $1.52 EPS and FY2030 earnings at $2.31 EPS.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Stock Down 8.3%

Shares of NASDAQ:ACHV opened at $2.65 on Friday. Achieve Life Sciences has a 52-week low of $1.84 and a 52-week high of $6.03. The firm has a fifty day moving average of $4.31 and a 200 day moving average of $4.30. The firm has a market capitalization of $141.06 million, a PE ratio of -2.04 and a beta of 1.81. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.14 and a current ratio of 4.39.

Hedge Funds Weigh In On Achieve Life Sciences

A number of large investors have recently added to or reduced their stakes in ACHV. AQR Capital Management LLC bought a new stake in Achieve Life Sciences in the first quarter worth $32,000. Franklin Resources Inc. boosted its position in Achieve Life Sciences by 81.3% during the second quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock valued at $10,077,000 after buying an additional 2,000,079 shares during the period. Stonepine Capital Management LLC bought a new position in shares of Achieve Life Sciences during the second quarter valued at about $753,000. Qube Research & Technologies Ltd bought a new position in shares of Achieve Life Sciences during the second quarter valued at about $232,000. Finally, Raymond James Financial Inc. increased its holdings in shares of Achieve Life Sciences by 57.1% in the second quarter. Raymond James Financial Inc. now owns 295,058 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 107,218 shares during the period. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences News Roundup

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $12 target while materially boosting long‑range EPS forecasts (FY2029 and FY2030 upgrades), signaling confidence in ACHV’s longer‑term commercial potential. Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright
• Positive Sentiment: A peer‑reviewed publication linked cytisinicline’s receptor profile to low nausea and favorable tolerability, a clinical differentiator that could support uptake if approved. Publication in Nicotine & Tobacco Research
• Positive Sentiment: Analysts and commentators are highlighting the upcoming PDUFA (June 20, 2026) and planned Phase 3 vaping cessation trial (ORCA‑V2 in 1H 2026) as major value catalysts toward a possible 1H‑2027 commercial launch if approved. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA…
• Positive Sentiment: Unusually large retail/institutional activity in call options suggests speculative bullish positioning ahead of the PDUFA and other near‑term catalysts. Investors Purchase Large Volume of Call Options on Achieve Life Sciences
• Neutral Sentiment: HC Wainwright also updated quarter‑by‑quarter 2026 EPS estimates (small quarterly losses expected) while keeping the Buy stance — important for modeling near‑term cash needs but not a directional change to the thesis. MarketBeat ACHV coverage
• Neutral Sentiment: The company’s Q4 2025 transcript and summary show a modest EPS miss and operational detail; useful for context on execution but not a game‑changer versus the upcoming FDA decision. Q4 2025 earnings call transcript Q4 2025 Earnings Call Summary
• Negative Sentiment: Mixed analyst revisions include downgrades to mid‑term EPS (HC Wainwright trimmed FY2027 and FY2028; Zacks cut FY2026/FY2027), which raises uncertainty on near‑term profitability and could pressure the stock ahead of the PDUFA. Market analyst estimate changes

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.